News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Painkiller Cox-2 inhibitor alternatives considered

Alternatives should now be considered for painkiller Cox-2 inhibitors

ACC says health practitioners should now consider prescribing alternatives for painkillers known as Cox-2 inhibitors in the wake of a review which concludes their benefits may be outweighed by increased risk of heart attacks and strokes.

“ACC is committed to helping provide claimants with safe medications for their treatment, but a Medsafe review released today indicates the risk of Cox-2 inhibitors to the general population is too high,” says ACC Corporate Medical Advisor Dr Kevin Morris.

He says the review has raised issues not only about Vioxx, which was withdrawn from the international market last year, but also about other Cox-2 inhibitors that remained in use such as Celebrex, Arcoxia, Mobic, Dynastrat and Bextra.

Dr Morris says Cox-2 inhibitors (also known as Cyclo-Oxygenase-2 inhibitors) were commonly prescribed to some ACC claimants for the treatment of pain and inflammation due to musculoskeletal disorders. He says they had been generally considered safer than other anti-inflammatory medications because they did not cause the same level of gastrointestinal side effects such as bleeding.

ACC is aware that Medsafe has noted today that there is currently insufficient evidence to quantify either the risks associated with the dose and duration of use for each Cox-2 inhibitor, or the factors which may increase risk of heart attacks and strokes.

However Medsafe has also noted that there is a real risk to the health of claimants with a previous history of heart attacks or strokes, or who have a strong family history of heart disease or a history of diabetes, hypertension, smoking or who are being treated for high cholesterol.

“We owe it to our claimants to minimise the possibility of adverse medical events,” Dr Morris says. “In Medsafe’s opinion, the possible increased risk of heart attack and stroke outweigh the benefits of Cox-2 inhibitors for the general population. ACC claimants taking Cox-2 inhibitors on a regular basis should now discuss the continuing use of these medications with their GP or specialist”.

The Best Practice Advocacy Centre has recently issued guidance on alternative analgesic options and management (NSAIDS – strategies for minimising harm) which is available online at

© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Legendary Bassist David Friesen Plays Wellington’s Newest Jazz Venue

Friesen is touring New Zealand to promote his latest album Another Time, Another Place, recorded live at Auckland's Creative Jazz Club in 2015. More>>

Howard Davis Review: The Father - Descending Into The Depths of Dementia

Florian Zeller's dazzling drama The Father explores the effects of a deeply unsettling illness that affects 62,000 Kiwis, a number expected to grow to 102,000 by 2030. More>>

Howard Davis Review: Blade Runner Redivivus

When Ridley Scott's innovative, neo-noir, sci-fi flick Blade Runner was originally released in 1982, at a cost of over $45 million, it was a commercial bomb. More>>

14-21 October: New Zealand Improv Festival In Wellington

Imagined curses, Shibuya’s traffic, the apocalypse, and motherhood have little in common, but all these and more serve as inspiration for the eclectic improvised offerings coming to BATS Theatre this October for the annual New Zealand Improv Festival. More>>


Bird Of The Year Off To A Flying Start

The competition asks New Zealanders to vote for their favourite bird in the hopes of raising awareness of the threats they face. More>>

Scoop Review Of Books:
K Emma Ng's Old Asian, New Asian

This book, written by a young second-generation Chinese New Zealander, gives many examples of the racism that Asian New Zealanders experience. More>>